Ann Lab Med.  2023 Mar;43(2):214-216. 10.3343/alm.2023.43.2.214.

Establishment of Reference Values for Non-HLA Antibodies in Patients With End-stage Renal Disease

• Shin KH
• Lee HJ
• Kim IY
• Choi BH
• Kim HH

• KMID: 2551702
• DOI: http://doi.org/10.3343/alm.2023.43.2.214

Figure

• 

  Fig. 1 Non-HLA antibody levels according to the pre-DSA status. (A) CXCL9, (B) GAPDH, and (C) TNFA levels in patients with and without pre-DSA (median [range]: CXCL9, 197.7 [43.0–4102.7] vs. 135.1 [23.1–3168.2]; GAPDH, 504.6 [72.7–11490.2] vs. 311.6 [27.2–7732.8]; TNFA, 457.6 [159–4629.5] vs. 359.3 [54.7–10403.3]). Abbreviations: CXCL9, C-X-C motif chemokine 9; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MFI, median fluorescence intensity; TNFA, tumor necrosis factor alpha; DSA, donor-specific antibodies.

Reference

1. Kamburova EG, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, van der Meer A, et al. 2018; Development and validation of a multiplex non-HLA antibody assay for the screening of kidney transplant recipients. Front Immunol. 9:3002. DOI: 10.3389/fimmu.2018.03002. PMID: 30631326. PMCID: PMC6315148.

2. Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, et al. 2019; Antibodies against ARHGDIB are associated with long‐term kidney graft loss. Am J Transplant. 19:3335–44. DOI: 10.1111/ajt.15493. PMID: 31194283. PMCID: PMC6899679.

3. Rampersad C, Shaw J, Gibson IW, Wiebe C, Rush DN, Nickerson PW, et al. 2020; Early antibody-mediated kidney transplant rejection associated with anti-vimentin antibodies: a case report. Am J Kidney Dis. 75:138–43. DOI: 10.1053/j.ajkd.2019.06.010. PMID: 31515140.

4. Kang H, Yoo J, Lee SY, Oh EJ. 2021; Causes of positive pretransplant crossmatches in the absence of donor-specific anti-human leukocyte antigen antibodies: a single-center experience. Ann Lab Med. 41:429–35. DOI: 10.3343/alm.2021.41.4.429. PMID: 33536364. PMCID: PMC7884190.

5. Miura K, Shirai Y, Kaneko N, Yabuuchi T, Ishizuka K, Horita S, et al. Chronic active antibody-mediated rejection with linear IgG deposition on glomerular capillaries in a kidney transplant recipient. Nephron. 2020; 144(Sl) 1:97–101. DOI: 10.1159/000511322. PMID: 33238286.

6. Riesco L, Irure J, Rodrigo E, Guiral S, Ruiz JC, Gómez J, et al. 2019; Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation. Transpl Immunol. 52:53–6. DOI: 10.1016/j.trim.2018.11.002. PMID: 30458294.

7. Rotondi M, Netti GS, Lazzeri E, Stallone G, Bertoni E, Chiovato L, et al. 2010; High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int. 23:465–75. DOI: 10.1111/j.1432-2277.2009.01006.x. PMID: 19929857.

8. Zhang X, Reinsmoen NL. 2017; Impact of non-human leukocyte antigen-specific antibodies in kidney and heart transplantation. Front Immunol. 8:434. DOI: 10.3389/fimmu.2017.00434. PMID: 28450866. PMCID: PMC5389972.

9. Cardinal H, Dieudé M, Hébert MJ. 2017; The emerging importance of non-HLA autoantibodies in kidney transplant complications. J Am Soc Nephrol. 28:400–6. DOI: 10.1681/ASN.2016070756. PMID: 27798244. PMCID: PMC5280028.